The EPS beat and raised guidance are modest positives, but the $385M legal reserve and GAAP earnings decline warrant caution. Monitor the legal settlement outcome and Nutrition segment recovery for sustained momentum. The raised EPS guidance suggests management confidence in H2 acceleration.
Price Chart
Executive Summary
Abbott reported Q2 2026 adjusted diluted EPS of $1.31, a 2.6% beat vs. consensus of $1.28, on reported sales of $12.593B (vs. $12.52B consensus). Comparable sales grew 4.8% YoY. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, while reaffirming comparable sales growth of 6.5%-7.5%. GAAP EPS was $0.53, depressed by $1.362B in specified items including $385M in legal reserves and $658M in intangible amortization.
Key Financial Metrics
Key Facts
- Adjusted diluted EPS of $1.31 beat consensus of $1.28 by 2.6%
- Reported sales of $12.593B vs. consensus of $12.52B, up 13.0% reported / 4.8% comparable YoY
- Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58
- Full-year 2026 comparable sales growth guidance reaffirmed at 6.5%-7.5%
- GAAP EPS was $0.53, impacted by $1.362B in specified items including $385M legal reserve
- Medical Devices comparable sales grew 8.4% YoY; Diabetes Care CGM sales grew 9.5% comparable
- Cancer Diagnostics (Exact Sciences) comparable sales grew 13.3% YoY
- Returned $2.1B to shareholders via dividends and share repurchases in Q2
Financial Impact
Adjusted EPS beat by ~$0.03; guidance raised by $0.07 at midpoint; $2.1B returned to shareholders
Risk Factors
- Nutrition segment continues to decline (-3.6% comparable YoY) due to pricing actions and volume weakness
- GAAP operating earnings fell 17.5% YoY due to acquisition-related costs and legal reserves
- Exact Sciences integration costs and $385M legal reserve create earnings noise
- Rapid/Molecular Diagnostics declining (-8.0% comparable) due to weaker respiratory season
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-048377 |
| Document: abt-20260716.htm | 0001628280-26-048377 |
| Document: 0001628280-26-048377-index-headers.html | 0001628280-26-048377 |
| Document: 0001628280-26-048377-index.html | 0001628280-26-048377 |
| Document: 0001628280-26-048377.txt | 0001628280-26-048377 |
| 8-K Data (Synthetic) | 0001628280-26-048377 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 today | ANALYST-UPGRADE | $98.00 awaiting T+5 | awaiting T+5 | — | $96.69 (−1.34%) |
Sep 14, 2026 18d ago | Court Ruling | $103.09 $102.98 | ▼ −0.11% | ▼ −1.77% | $96.69 (−6.21%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.69 (−11.88%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.69 (−11.88%) |
Jul 31, 2026 9w ago | Institutional Cluster | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.69 (−8.52%) |
Jul 31, 2026 9w ago | Court Ruling | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.69 (−8.52%) |
Jul 24, 2026 10w ago | Court Ruling | $103.06 $105.61 | ▲ +2.47% | ▲ +2.10% | $96.69 (−6.18%) |
Jul 16, 2026 11w ago | 8-K | $98.83 $100.75 | ▲ +1.94% | ▲ +3.61% | $96.69 (−2.17%) |
Jul 14, 2026 11w ago | Court Ruling | $88.96 $101.66 | ▲ +14.28% | ▲ +15.57% | $96.69 (+8.69%) |
Jul 7, 2026 12w ago | Court Ruling | $95.84 $88.96 | ▼ −7.18% | ▼ −7.73% | $96.69 (+0.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access